Robert L. Vessella
#129,718
Most Influential Person Now
Robert L. Vessella's AcademicInfluence.com Rankings
Robert L. Vessellaphilosophy Degrees
Philosophy
#6260
World Rank
#9262
Historical Rank
Logic
#3440
World Rank
#4596
Historical Rank
Robert L. Vessellabiology Degrees
Biology
#8466
World Rank
#11543
Historical Rank
Cell Biology
#332
World Rank
#340
Historical Rank
Molecular Biology
#1082
World Rank
#1107
Historical Rank
Biochemistry
#1230
World Rank
#1349
Historical Rank
Download Badge
Philosophy Biology
Robert L. Vessella's Degrees
- PhD Biochemistry University of Washington
- Bachelors Chemistry University of Washington
Why Is Robert L. Vessella Influential?
(Suggest an Edit or Addition)Robert L. Vessella's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Circulating microRNAs as stable blood-based markers for cancer detection (2008) (7285)
- Molecular determinants of resistance to antiandrogen therapy (2004) (2298)
- Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. (2008) (1370)
- Absolute quantification by droplet digital PCR versus analog real-time PCR (2013) (1052)
- Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. (2009) (999)
- MicroRNA expression profiling in prostate cancer. (2007) (932)
- Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. (2008) (819)
- Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. (2001) (775)
- EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent (2012) (724)
- Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. (2010) (707)
- Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. (1998) (698)
- Changes in circulating microRNA levels associated with prostate cancer (2012) (640)
- Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants (2011) (579)
- TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. (2006) (539)
- Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. (1999) (514)
- The value of serum prostate specific antigen determinations before and after radical prostatectomy. (1989) (504)
- Basic Mechanisms Responsible for Osteolytic and Osteoblastic Bone Metastases (2006) (485)
- HIF induces human embryonic stem cell markers in cancer cells. (2011) (461)
- Increased AKT Activity Contributes to Prostate Cancer Progression by Dramatically Accelerating Prostate Tumor Growth and Diminishing p27Kip1 Expression* (2000) (411)
- Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling. (2017) (407)
- Screening for prostatic carcinoma with prostate specific antigen. (1992) (392)
- Substantial inter-individual and limited intra-individual genomic diversity among tumors from men with metastatic prostate cancer (2016) (326)
- Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance (2010) (319)
- Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. (2003) (306)
- A molecular correlate to the Gleason grading system for prostate adenocarcinoma. (2006) (289)
- Prostatic specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer. (1987) (285)
- TMPRSS2:ERG Fusion Identifies a Subgroup of Prostate Cancers with a Favorable Prognosis (2008) (264)
- Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers (2011) (261)
- Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer (2016) (255)
- Androgen Receptor Variants Occur Frequently in Castration Resistant Prostate Cancer Metastases (2011) (253)
- Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. (2003) (252)
- A Gain-of-Function Mutation in DHT Synthesis in Castration-Resistant Prostate Cancer (2013) (244)
- Osteoprotegerin and rank ligand expression in prostate cancer. (2001) (243)
- Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer (2014) (228)
- Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis. (2005) (225)
- Disseminated Tumor Cells in Prostate Cancer Patients after Radical Prostatectomy and without Evidence of Disease Predicts Biochemical Recurrence (2009) (216)
- Androgen receptor splice variants determine taxane sensitivity in prostate cancer. (2012) (213)
- Cell-cell interaction in prostate gene regulation and cytodifferentiation. (1997) (210)
- Establishment and characterization of osseous prostate cancer models: Intra‐tibial injection of human prostate cancer cells (2002) (203)
- Prostate Stem Cell Antigen Is Overexpressed in Prostate Cancer Metastases (2005) (203)
- AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression (2011) (192)
- Placental alkaline phosphatase as a tumor marker for seminoma. (1982) (187)
- SnoRNA U50 is a candidate tumor-suppressor gene at 6q14.3 with a mutation associated with clinically significant prostate cancer. (2007) (179)
- DAB2IP coordinates both PI3K-Akt and ASK1 pathways for cell survival and apoptosis (2009) (179)
- In vivo Effects of the Human Type I Insulin-Like Growth Factor Receptor Antibody A12 on Androgen-Dependent and Androgen-Independent Xenograft Human Prostate Tumors (2005) (177)
- Differential expression of osteonectin/SPARC during human prostate cancer progression. (2000) (174)
- LuCaP Prostate Cancer Patient‐Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease and Serve as Models for Evaluating Cancer Therapeutics (2017) (172)
- Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer. (1999) (172)
- Cancer micrometastasis and tumour dormancy (2008) (171)
- Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer (2005) (171)
- Elevation of cytokine levels in cachectic patients with prostate carcinoma (2003) (170)
- Circulating microRNA Profiling Identifies a Subset of Metastatic Prostate Cancer Patients with Evidence of Cancer-Associated Hypoxia (2013) (166)
- LuCaP 35: A new model of prostate cancer progression to androgen independence (2003) (157)
- Deletion, mutation, and loss of expression of KLF6 in human prostate cancer. (2003) (153)
- The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late‐stage prostate cancer (2006) (152)
- Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23. (1996) (151)
- Screening for prostatic carcinoma with prostate specific antigen: results of the second year. (1993) (150)
- Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer (2013) (148)
- A, B, H antigens in transitional cell tumors of the urinary bladder. Correlation with the clinical course (1979) (144)
- Expression of Androgen Receptor Coregulators in Prostate Cancer (2004) (143)
- APC/CTNNB1 (β‐catenin) pathway alterations in human prostate cancers (2002) (141)
- KLF5 is frequently deleted and down‐regulated but rarely mutated in prostate cancer (2003) (141)
- The effect of radiation therapy after radical prostatectomy in patients with elevated prostate specific antigen levels. (1990) (141)
- TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer (2013) (140)
- Correlation of vascular permeability and blood flow with monoclonal antibody uptake by human Clouser and renal cell xenografts. (1988) (140)
- FOXO1A is a candidate for the 13q14 tumor suppressor gene inhibiting androgen receptor signaling in prostate cancer. (2006) (139)
- Expression of SLCO Transport Genes in Castration-Resistant Prostate Cancer and Impact of Genetic Variation in SLCO1B3 and SLCO2B1 on Prostate Cancer Outcomes (2011) (137)
- Metastatic progression of prostate cancer and e-cadherin regulation by zeb1 and SRC family kinases. (2011) (137)
- The current state of preclinical prostate cancer animal models (2008) (136)
- Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model. (2007) (134)
- Histopathological assessment of prostate cancer bone osteoblastic metastases. (2008) (133)
- Overexpression of androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer (2012) (130)
- The androgen‐regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma (2008) (126)
- Early tumor cell dissemination in patients with clinically localized carcinoma of the prostate. (1997) (126)
- Detection and isolation of prostate cancer cells from peripheral blood and bone marrow. (2003) (125)
- SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer (2015) (124)
- Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. (2001) (123)
- Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system. (1997) (120)
- Evaluation of the Abbott IMx automated immunoassay of prostate-specific antigen. (1992) (118)
- Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models (2017) (118)
- Novel biomarkers for prostate cancer including noncoding transcripts. (2009) (118)
- Ubiquitin E3 ligase WWP1 as an oncogenic factor in human prostate cancer (2007) (117)
- Serum Glutamate Levels Correlate with Gleason Score and Glutamate Blockade Decreases Proliferation, Migration, and Invasion and Induces Apoptosis in Prostate Cancer Cells (2012) (117)
- Osteoprotegerin in prostate cancer bone metastasis. (2005) (114)
- A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, analytical performance, and diagnostic accuracy. (2008) (113)
- Biotin reagents for antibody pretargeting. 3. Synthesis, radioiodination, and evaluation of biotinylated starburst dendrimers. (1998) (111)
- Mechanisms, Hypotheses and Questions Regarding Prostate Cancer Micrometastases to Bone (1998) (111)
- LIV-1 Promotes Prostate Cancer Epithelial-to-Mesenchymal Transition and Metastasis through HB-EGF Shedding and EGFR-Mediated ERK Signaling (2011) (103)
- The role of tumor microenvironment in prostate cancer bone metastasis (2007) (102)
- Tumor cell dormancy: An NCI workshop report (2007) (101)
- Prostate cancer expression of runt‐domain transcription factor Runx2, a key regulator of osteoblast differentiation and function (2003) (101)
- Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis (2009) (99)
- Dietary protein restriction inhibits tumor growth in human xenograft models of prostate and breast cancer (2013) (98)
- Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases (2007) (97)
- VEGF/neuropilin-2 regulation of Bmi-1 and consequent repression of IGF-IR define a novel mechanism of aggressive prostate cancer. (2012) (95)
- Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients (2003) (94)
- Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer (2012) (93)
- Reagents for astatination of biomolecules: comparison of the in vivo distribution and stability of some radioiodinated/astatinated benzamidyl and nido-carboranyl compounds. (2004) (92)
- Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: The effect of bisphosphonate therapy on bone scintigraphy results (2004) (92)
- Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer. (2002) (92)
- Characterization of single disseminated prostate cancer cells reveals tumor cell heterogeneity and identifies dormancy associated pathways (2014) (88)
- Combined In vivo Effect of A12, a Type 1 Insulin-Like Growth Factor Receptor Antibody, and Docetaxel against Prostate Cancer Tumors (2006) (88)
- Activation of P-TEFb by Androgen Receptor-Regulated Enhancer RNAs in Castration-Resistant Prostate Cancer. (2016) (87)
- Prostate-specific membrane antigen directed selective thrombotic infarction of tumors. (2002) (87)
- Molecular characterization of prostatic small‐cell neuroendocrine carcinoma (2003) (86)
- C-kit and its ligand stem cell factor: potential contribution to prostate cancer bone metastasis. (2008) (86)
- RAD21 and KIAA0196 at 8q24 are amplified and overexpressed in prostate cancer (2004) (85)
- DIAPH3 governs the cellular transition to the amoeboid tumour phenotype (2012) (85)
- Metastases of prostate cancer express estrogen receptor-beta. (2004) (84)
- Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment (2006) (83)
- Antibody immunity to prostate cancer associated antigens can be detected in the serum of patients with prostate cancer. (2000) (83)
- Prostatic cell lineage markers: Emergence of BCL2+ cells of human prostate cancer xenograft LuCaP 23 following castration (1996) (82)
- APC/CTNNB1 (beta-catenin) pathway alterations in human prostate cancers. (2002) (80)
- The value of a reverse transcriptase polymerase chain reaction assay in preoperative staging and followup of patients with prostate cancer. (1998) (79)
- HOXB13 G84E Mutation in Finland: Population-Based Analysis of Prostate, Breast, and Colorectal Cancer Risk (2013) (78)
- Human Prostate Cancer in a Clinically Relevant Xenograft Mouse Model: Identification of β(1,6)-Branched Oligosaccharides as a Marker of Tumor Progression (2012) (77)
- Application of affymetrix array and massively parallel signature sequencing for identification of genes involved in prostate cancer progression (2005) (76)
- Targeting FOXA1-mediated repression of TGF-&bgr; signaling suppresses castration-resistant prostate cancer progression (2018) (76)
- Comparison of immunohistochemistry with reverse transcription-PCR for the detection of micrometastatic prostate cancer in lymph nodes. (2003) (75)
- Monoclonal antibodies to human renal cell carcinoma: recognition of shared and restricted tissue antigens. (1985) (73)
- Overexpression of protease‐activated receptors‐1,‐2, and‐4 (PAR‐1, ‐2, and ‐4) in prostate cancer (2007) (73)
- Reagents for astatination of biomolecules. 2. Conjugation of anionic boron cage pendant groups to a protein provides a method for direct labeling that is stable to in vivo deastatination. (2007) (72)
- Molecular Alterations in Prostate Carcinomas that Associate with In vivo Exposure to Chemotherapy: Identification of a Cytoprotective Mechanism Involving Growth Differentiation Factor 15 (2007) (72)
- Comparative analyses of chromosome alterations in soft-tissue metastases within and across patients with castration-resistant prostate cancer. (2009) (72)
- Radiobiological comparison of external beam irradiation and radioimmunotherapy in renal cell carcinoma xenografts. (1989) (71)
- RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid (2008) (70)
- Prostate cancer-associated membrane type 1-matrix metalloproteinase: a pivotal role in bone response and intraosseous tumor growth. (2007) (70)
- A Positive Role of c-Myc in Regulating Androgen Receptor and its Splice Variants in Prostate Cancer (2019) (70)
- Genetic alterations and changes in expression of histone demethylases in prostate cancer (2010) (69)
- Targeted androgen pathway suppression in localized prostate cancer: a pilot study. (2014) (69)
- Detection of circulating prostate cells by reverse transcriptase-polymerase chain reaction of human glandular kallikrein (hK2) and prostate-specific antigen (PSA) messages. (1997) (68)
- Loss of TGF-β Responsiveness in Prostate Stromal Cells Alters Chemokine Levels and Facilitates the Development of Mixed Osteoblastic/Osteolytic Bone Lesions (2012) (67)
- Detection and characterization of circulating and disseminated prostate cancer cells. (2007) (66)
- Targeting Factors Involved in Bone Remodeling as Treatment Strategies in Prostate Cancer Bone Metastasis (2006) (66)
- Genomic alterations indicate tumor origin and varied metastatic potential of disseminated cells from prostate cancer patients. (2008) (65)
- Advancing Treatment for Metastatic Bone Cancer: Consensus Recommendations from the Second Cambridge Conference (2008) (65)
- Cabozantinib Inhibits Growth of Androgen-Sensitive and Castration-Resistant Prostate Cancer and Affects Bone Remodeling (2013) (64)
- Early detection of recurrent prostate cancer with an ultrasensitive chemiluminescent prostate-specific antigen assay. (1997) (63)
- Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient‐derived xenograft (PDX) models (2018) (62)
- Preparation and evaluation of para-[211At]astatobenzoyl labeled anti-renal cell carcinoma antibody A6H F(ab')2. In vivo distribution comparison with para-[125I]iodobenzoyl labeled A6H F(ab')2. (1993) (62)
- Cell proliferation and apoptosis during prostatic tumor xenograft involution and regrowth after castration (1996) (61)
- Nemo‐like kinase induces apoptosis and inhibits androgen receptor signaling in prostate cancer cells (2009) (61)
- An Antibody Targeting the Type I Insulin-like Growth Factor Receptor Enhances the Castration-Induced Response in Androgen-Dependent Prostate Cancer (2007) (61)
- Placental bone morphogenetic protein (PLAB) gene expression in normal, pre‐malignant and malignant human prostate: Relation to tumor development and progression (2001) (61)
- Human Prostate Cancer Harbors the Stem Cell Properties of Bone Marrow Mesenchymal Stem Cells (2011) (61)
- Effects of androgen deprivation therapy and bisphosphonate treatment on bone in patients with metastatic castration‐resistant prostate cancer: Results from the University of Washington Rapid Autopsy Series (2013) (60)
- Prostate short-chain dehydrogenase reductase 1 (PSDR1): a new member of the short-chain steroid dehydrogenase/reductase family highly expressed in normal and neoplastic prostate epithelium. (2001) (59)
- Osteoclast-Derived Matrix Metalloproteinase-9 Directly Affects Angiogenesis in the Prostate Tumor–Bone Microenvironment (2010) (58)
- A quantitative model for the dynamics of serum prostate-specific antigen as a marker for cancerous growth: an explanation for a medical anomaly. (2001) (57)
- Bone morphogenetic protein 7 is expressed in prostate cancer metastases and its effects on prostate tumor cells depend on cell phenotype and the tumor microenvironment. (2010) (57)
- Estradiol suppresses tissue androgens and prostate cancer growth in castration resistant prostate cancer (2010) (57)
- Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases (2013) (57)
- Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas (2015) (56)
- The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft (2004) (55)
- Amplification and overexpression of prosaposin in prostate cancer (2005) (54)
- Defining the region(s) of deletion at 6q16–q22 in human prostate cancer (2002) (53)
- Inhibition of androgen-independent growth of prostate cancer xenografts by 17beta-estradiol. (2002) (52)
- The miR‐15a‐miR‐16‐1 locus is homozygously deleted in a subset of prostate cancers (2011) (52)
- Identification and characterization of leukotriene D4 receptors in adult and fetal human lung. (1985) (52)
- Issues in the assessment of PSA immunoassays. (1993) (52)
- Improved reverse transcriptase-polymerase chain reaction protocol with exogenous internal competitive control for prostate-specific antigen mRNA in blood and bone marrow. (1997) (51)
- High-affinity peptide ligands to prostate-specific antigen identified by polysome selection. (1997) (51)
- Effects of phenylbutyrate on proliferation and apoptosis in human prostate cancer cells in vitro and in vivo. (1999) (51)
- A neuroendocrine/small cell prostate carcinoma xenograft-LuCaP 49. (2002) (50)
- Lineage relationship between LNCaP and LNCaP‐derived prostate cancer cell lines (2004) (50)
- High prevalence of antibodies against HERV-K10 in patients with testicular cancer but not with AIDS. (1999) (49)
- A very sensitive coupled luminescent assay for cytotoxicity and complement-mediated lysis. (1997) (49)
- Fibronectin enhances in vitro monocyte-macrophage-mediated tumoricidal activity. (1982) (48)
- Characterization of C4–2 Prostate Cancer Bone Metastases and Their Response to Castration (2003) (48)
- Reduced Expression of the Androgen Receptor by Third Generation of Antisense Shows Antitumor Activity in Models of Prostate Cancer (2011) (46)
- Molecular assays for the detection of microRNAs in prostate cancer (2009) (46)
- Characterization and comparison of human monocyte- and macrophage-induced tumor cell cytotoxicity. (1979) (46)
- The enhanced detection of persistent disease after prostatectomy with a new prostate specific antigen immunoassay. (1993) (46)
- Telomerase activity in disseminated prostate cancer cells (2006) (46)
- Free and complexed prostate-specific antigen serum ratios to predict probability of primary prostate cancer and benign prostatic hyperplasia. (1996) (45)
- Stromal mesenchyme cell genes of the human prostate and bladder (2005) (45)
- Cellular Adhesion Promotes Prostate Cancer Cells Escape from Dormancy (2015) (45)
- Preclinical models of prostate cancer. (1996) (45)
- Evaluation of the branched-chain DNA assay for measurement of RNA in formalin-fixed tissues. (2007) (44)
- Expression of the human cachexia‐associated protein (HCAP) in prostate cancer and in a prostate cancer animal model of cachexia (2003) (44)
- Antibody fragments in tumor pretargeting. Evaluation of biotinylated Fab' colocalization with recombinant streptavidin and avidin. (1996) (44)
- Development of new biotin/streptavidin reagents for pretargeting. (1999) (43)
- Dormancy in solid tumors: implications for prostate cancer (2013) (43)
- The expression of osteoclastogenesis‐associated factors and osteoblast response to osteolytic prostate cancer cells (2010) (41)
- A Paracrine Role for IL6 in Prostate Cancer Patients: Lack of Production by Primary or Metastatic Tumor Cells (2015) (41)
- Development, validation and application of a stable isotope dilution liquid chromatography electrospray ionization/selected reaction monitoring/mass spectrometry (SID-LC/ESI/SRM/MS) method for quantification of keto-androgens in human serum (2013) (41)
- The detection and isolation of viable prostate-specific antigen positive epithelial cells by enrichment: a comparison to standard prostate-specific antigen reverse transcriptase polymerase chain reaction and its clinical relevance in prostate cancer. (2007) (40)
- Characterizing the molecular features of ERG‐positive tumors in primary and castration resistant prostate cancer (2016) (40)
- Urinary prostate specific antigen levels after radical prostatectomy. (1994) (40)
- Methylation profiling identified novel differentially methylated markers including OPCML and FLRT2 in prostate cancer (2016) (39)
- Localization of human renal cell carcinoma xenografts with a tumor-preferential monoclonal antibody. (1985) (39)
- Epigenetically altered miR-193b targets cyclin D1 in prostate cancer (2015) (37)
- Monoclonal antibody‐targeted radiotherapy of renal cell carcinoma using a nude mouse model (1988) (37)
- Identification of specific binding sites for leukotriene C4 in human fetal lung. (1984) (36)
- Bicalutamide increases phospho-Akt levels through Her2 in patients with prostate cancer. (2007) (36)
- Host-derived RANKL is responsible for osteolysis in a C4-2 human prostate cancer xenograft model of experimental bone metastases (2007) (36)
- Prostate cancer cell phenotypes based on AGR2 and CD10 expression (2012) (36)
- Inhibition of CCL2 Signaling in Combination with Docetaxel Treatment Has Profound Inhibitory Effects on Prostate Cancer Growth in Bone (2013) (36)
- Trends in immunoassays of prostate-specific antigen: serum complexes and ultrasensitivity. (1993) (36)
- Targeting GPR30 with G-1: a new therapeutic target for castration-resistant prostate cancer. (2014) (35)
- In vitro binding evaluation of 177Lu-AMBA, a novel 177Lu-labeled GRP-R agonist for systemic radiotherapy in human tissues (2008) (35)
- AR-regulated TWEAK-FN14 pathway promotes prostate cancer bone metastasis. (2014) (35)
- Tumour cell survival mechanisms in lethal metastatic prostate cancer differ between bone and soft tissue metastases (2013) (35)
- Dosimetry of solid tumors. (1993) (35)
- Single cell transcriptomic analysis of prostate cancer cells (2013) (34)
- Epithelial mesenchymal-like transition occurs in a subset of cells in castration resistant prostate cancer bone metastases (2016) (34)
- Src promotes castration-recurrent prostate cancer through androgen receptor-dependent canonical and non-canonical transcriptional signatures (2016) (34)
- Estrogen effects on tubulin expression and taxane mediated cytotoxicity in prostate cancer cells (2005) (34)
- Efficacy studies of an antibody‐drug conjugate PSMA‐ADC in patient‐derived prostate cancer xenografts (2015) (33)
- Engineering the isoelectric point of a renal cell carcinoma targeting antibody greatly enhances scFv solubility. (1998) (33)
- Inhibition of angiopoietin‐2 in LuCaP 23.1 prostate cancer tumors decreases tumor growth and viability (2010) (33)
- Xenograft Models of Human Prostate Cancer (2007) (33)
- Biotin reagents in antibody pretargeting. 6. Synthesis and in vivo evaluation of astatinated and radioiodinated aryl- and nido-carboranyl-biotin derivatives. (2004) (33)
- SnoRNA U 50 is a candidate tumor-suppressor gene at 6 q 14 . 3 with a mutation associated with clinically significant prostate cancer (2008) (32)
- Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms (2005) (32)
- Probability of prostate cancer detection based on results of a multicenter study using the AxSYM free PSA and total PSA assays. (2000) (32)
- Protease‐activated receptor‐1 is upregulated in reactive stroma of primary prostate cancer and bone metastasis (2009) (31)
- Hyperbaric oxygen does not accelerate latent in vivo prostate cancer: implications for the treatment of radiation‐induced haemorrhagic cystitis (2004) (31)
- Inhibition of androgen-independent prostate cancer by estrogenic compounds is associated with increased expression of immune-related genes. (2006) (31)
- A human embryonal-yolk sac carcinoma model system in athymic mice. (1985) (31)
- A Three-Marker FISH Panel Detects More Genetic Aberrations of AR, PTEN and TMPRSS2/ERG in Castration-Resistant or Metastatic Prostate Cancers than in Primary Prostate Tumors (2013) (30)
- LNCaP produces both putative zymogen and inactive, free form of prostate‐specific antigen (1998) (29)
- Streptavidin in antibody pretargeting. 2. Evaluation Of methods for decreasing localization of streptavidin to kidney while retaining its tumor binding capacity. (1998) (29)
- Advances in Treating Metastatic Bone Cancer: Summary Statement for the First Cambridge Conference (2006) (29)
- A human embryonal—yolk sac carcinoma model system in athymic mice (1985) (28)
- Is SP-1 a marker for testicular cancer? (1980) (28)
- Preparation and biodistribution of copper-67-labeled porphyrins and porphyrin-A6H immunoconjugates. (1997) (28)
- Differential expression of IL-17RC isoforms in androgen-dependent and androgen-independent prostate cancers. (2007) (27)
- Streptavidin in antibody pretargeting. Comparison of a recombinant streptavidin with two streptavidin mutant proteins and two commercially available streptavidin proteins. (1998) (27)
- Decreased expression of prostatic secretory protein PSP94 in prostate cancer. (1993) (27)
- Prostate-specific antigen: characterization of epitopes by synthetic peptide mapping and inhibition studies. (1997) (27)
- Restoration of tumor suppression in prostate cancer by targeting the E3 ligase E6AP (2016) (27)
- Targeted chemotherapy with cytotoxic bombesin analogue AN‐215 inhibits growth of experimental human prostate cancers (2006) (27)
- The role of the microenvironment-dormant prostate disseminated tumor cells in the bone marrow. (2014) (26)
- Tumor necrosis factor receptor associated factor-4: an adapter protein overexpressed in metastatic prostate cancer is regulated by microRNA-29a. (2013) (26)
- HE3235 inhibits growth of castration-resistant prostate cancer. (2009) (25)
- Chemotherapy-Induced Monoamine Oxidase Expression in Prostate Carcinoma Functions as a Cytoprotective Resistance Enzyme and Associates with Clinical Outcomes (2014) (25)
- Serum prosaposin levels are increased in patients with advanced prostate cancer (2012) (25)
- Newer applications of serum prostate-specific antigen in the management of prostate cancer. (1994) (24)
- Reagents for astatination of biomolecules. 5. Evaluation of hydrazone linkers in (211)At- and (125)I-labeled closo-decaborate(2-) conjugates of Fab' as a means of decreasing kidney retention. (2011) (24)
- Heteroconjugate antibody-directed killing of autologous human renal carcinoma cells by in vitro-activated lymphocytes. (1990) (24)
- Induction of neuronal apoptosis inhibitory protein expression in response to androgen deprivation in prostate cancer. (2010) (24)
- Lineage relationship of prostate cancer cell types based on gene expression (2011) (23)
- Intermittent androgen suppression in the LuCaP 23.12 prostate cancer xenograft model (2000) (22)
- Comprehensive mutational analysis and mRNA isoform quantification of TP63 in normal and neoplastic human prostate cells (2009) (22)
- Issues in the assessment of prostate-specific antigen immunoassays. An update. (1997) (22)
- Molecular assays for the detection of prostate tumor derived nucleic acids in peripheral blood (2010) (21)
- Prostate cancer derived prostatic acid phosphatase promotes an osteoblastic response in the bone microenvironment (2014) (21)
- Osteoblast-derived factors induce an expression signature that identifies prostate cancer metastasis and hormonal progression. (2009) (21)
- Haploinsufficiency and reduced expression of genes localized to the 8p chromosomal region in human prostate tumors (2003) (19)
- Radioiodinated monoclonal antibodies in the imaging and treatment of human renal cell carcinoma xenografts in nude mice. (1988) (19)
- Microsatellite instability and mismatch repair target gene mutations in cell lines and xenografts of prostate cancer (2006) (19)
- Radioimmunoscintigraphy and radioimmunotherapy of renal cell carcinoma xenografts. (1987) (19)
- The Role of Calmodulin in Human Natural Killer Cell Activity (1983) (19)
- Circulating tumor cells as a marker of response: implications for determining treatment efficacy and evaluating new agents (2012) (19)
- Serial prostate specific antigen, free-to-total prostate specific antigen ratio and complexed prostate specific antigen for the diagnosis of prostate cancer. (2001) (18)
- Heterogeneity among human lymphocyte effector cells mediating spontaneous lymphocyte‐mediated cytotoxicity (1978) (18)
- The biology and clinical implications of prostate cancer dormancy and metastasis (2016) (18)
- A novel four-color fluorescence in situ hybridization assay for the detection of TMPRSS2 and ERG rearrangements in prostate cancer. (2013) (18)
- Prostate Cancer–Associated Gene Expression Alterations Determined from Needle Biopsies (2009) (17)
- WDR19 Expression is Increased in Prostate Cancer Compared with Normal Cells, but Low-Intensity Expression in Cancers is Associated with Shorter Time to Biochemical Failures and Local Recurrence (2008) (17)
- A DNA methylation microarray-based study identifies ERG as a gene commonly methylated in prostate cancer (2011) (17)
- Characterization of an Abiraterone Ultraresponsive Phenotype in Castration-Resistant Prostate Cancer Patient-Derived Xenografts (2016) (17)
- Human pHyde is not a classical tumor suppressor gene in prostate cancer (2003) (16)
- Mechanistic Studies of the Effects of Anti-factor H Antibodies on Complement-mediated Lysis* (2000) (16)
- Serum percent free prostate-specific antigen in metastatic prostate cancer. (1998) (16)
- Advances in Brief Prostate-localized and Androgen-regulated Expression of the Membrane-bound Serine Protease TMPRSS 2 1 (1999) (16)
- A highly restricted antigen for renal cell carcinoma defined by a monoclonal antibody. (1985) (16)
- Multicenter Evaluation of the Performance and Clinical Utility in Longitudinal Monitoring of the Bayer Immuno 1™ Complexed PSA Assay (1999) (16)
- Synthesis and nca-radioiodination of arylstannyl-cobalamin conjugates. Evaluation of aryliodo-cobalamin conjugate binding to transcobalamin II and biodistribution in mice. (1996) (15)
- Laminin selectively enhances monocyte-macrophage-mediated tumoricidal activity. (1985) (15)
- Differentiation potential of human embryonal carcinoma cell lines. (1984) (15)
- Monoclonal antibodies in human renal cell carcinoma and their use in radioimmune localization and therapy of tumor xenografts. (1985) (15)
- HOXB 13 G 84 E Mutation in Finland : Population-Based Analysis of Prostate , Breast , and Colorectal Cancer Risk (2013) (14)
- Streptavidin in antibody pretargeting. 3. Comparison of biotin binding and tissue localization of 1,2-cyclohexanedione and succinic anhydride modified recombinant streptavidin. (2002) (14)
- Isolation and characterization of human and mouse WDR19,a novel WD-repeat protein exhibiting androgen-regulated expression in prostate epithelium. (2003) (14)
- Contribution of ARLTS1 Cys148Arg (T442C) Variant with Prostate Cancer Risk and ARLTS1 Function in Prostate Cancer Cells (2011) (14)
- Monoclonal antibodies in urology. (1983) (14)
- Glutathione and glutathione S-transferase in benign and malignant prostate cell lines and prostate tissues. (1996) (14)
- Spheroid culture of LuCaP 147 as an authentic preclinical model of prostate cancer subtype with SPOP mutation and hypermutator phenotype. (2014) (14)
- Bayer immuno 1™ PSA assay: An automated, ultrasensitive method to quantitate total PSA in serum (1998) (13)
- Metastatic conventional prostatic adenocarcinoma with diffuse chromogranin A and androgen receptor positivity (2004) (13)
- Recurrent SKIL-activating rearrangements in ETS-negative prostate cancer (2015) (13)
- NADiA ProsVue prostate-specific antigen slope is an independent prognostic marker for identifying men at reduced risk of clinical recurrence of prostate cancer after radical prostatectomy. (2012) (13)
- SRRM 4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer (2015) (12)
- Conversion of Prostate Adenocarcinoma to Small Cell Carcinoma‐Like by Reprogramming (2016) (12)
- Radioimmunoconjugates in Renal Cell Carcinoma (1991) (12)
- Haploinsufficiency and reduced expression of genes localized to the 8p chromosomal region in human prostate tumors. (2003) (12)
- Cross-reactivity of ten anti-prostate-specific antigen monoclonal antibodies with human glandular kallikrein. (1997) (12)
- On the possibility of 'real-time' Monte Carlo calculations for the estimation of absorbed dose in radioimmunotherapy. (1989) (12)
- Transforming Growth Factor-β–Stimulated Clone-22 Is an Androgen-Regulated Gene That Enhances Apoptosis in Prostate Cancer following Insulin-Like Growth Factor-I Receptor Inhibition (2009) (12)
- The role of calmodulin in human renal cell carcinoma. (1983) (12)
- Recurrent SKIL-activating rearrangements in ETS-negative prostate cancer. (2015) (12)
- Corrigendum to “A multicenter evaluation of the PCA3 molecular urine test: Pre-analytical effects, analytical performance, and diagnostic accuracy” [Clinica Chimica Acta 389 (2008)L-6] (2009) (11)
- Evaluationof the Abbott lMx#{174} Automated Immunoassayof Prostate-SpecificAntigen (1992) (11)
- CORRELATION OF SPONTANEOUS LEUKOCYTE BLASTOGENESIS WITH HUMAN RENAL ALLOGRAFT REJECTION (1977) (11)
- Monoclonal antibody Fab' fragment cross-linking using equilibrium transfer alkylation reagents. A strategy for site-specific conjugation of diagnostic and therapeutic agents with F(ab')2 fragments. (1994) (11)
- THE USE OF % FREE PSA (%fPSA) TO PREDICT PROSTATE CANCER PROBABILITIES: AN ELEVEN CENTER PROSPECTIVE STUDY USING AN AUTOMATED IMMUNOASSAY SYSTEM IN A POPULATION WITH NON-SUSPICIOUS DRE (1999) (10)
- Targeting GPR 30 with G-1 : a new therapeutic target for castration-resistant prostate cancer (2014) (10)
- Protease-activated receptor 2 signaling upregulates angiogenic growth factors in renal cell carcinoma. (2013) (10)
- 5α-reductase inhibition suppresses testosterone-induced initial regrowth of regressed xenograft prostate tumors in animal models. (2013) (9)
- Dosimetry and pharmacokinetics of monoclonal antibody A6H with human renal cell carcinoma xenografts: single dose study. (1991) (9)
- High-Resolution Genomic Profiling of Disseminated Tumor Cells in Prostate Cancer. (2016) (9)
- Effect of chemical modification strategy on the characteristics of copper-67-Labeled immunoconjugates, Part I: Immunoreactivity (1997) (9)
- Neoadjuvant androgen pathway suppression prior to prostatectomy. (2012) (8)
- Detection, Isolation and Study of Disseminated Prostate Cancer Cells in the Peripheral Blood and Bone Marrow (2003) (8)
- Bone morphogenetic proteins and prostate cancer: evolving complexities. (2007) (8)
- Heterogeneity of human lymphocyte Fc receptors: studies using heat-aggregated and antigen-complexed IgG from human, rabbit, guinea pig, horse and goat. (1982) (8)
- Acid phosphatase for monitoring prostatic carcinoma. Comparison of radioimmunoassay and enzymatic techniques. (1983) (8)
- The kinetic properties of the ecto-ATPase of human peripheral blood lymphocytes and of chronic lymphatic leukemia cells. (1983) (8)
- DIAPH 3 governs the cellular transition to the amoeboid tumor phenotype (2012) (7)
- Expressionof Runt-Domain Transcription FactorRunx 2 , aKeyRegulatorof OsteoblastDifferentiation and Function (2003) (7)
- Targeting FOXA 1-mediated repression of TGF-b signaling suppresses castration-resistant prostate cancer progression (2019) (7)
- CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells. (2015) (7)
- Host response to allogeneic implants in the anterior chamber of the rat eye. (1978) (6)
- Monoclonal antibodies against nuclear casein kinase NII (PK-N2). (1990) (6)
- [In vitro and in vivo models developed from human prostatic cancer]. (1997) (5)
- A novel co-stimulatory T cell antigen co-expressed on renal cell carcinoma. (1995) (5)
- Prostate Cancer Characteristics Associated with Response to Pre-Receptor Targeting of the Androgen Axis (2014) (5)
- s-SHIP expression identifies a subset of murine basal prostate cells as neonatal stem cells (2016) (5)
- Reprogramming of Prostate Cancer Cells - Technical Challenges (2014) (4)
- The anterior chamber of the eye: a sensitive site for the detection of cross-reacting alloantigens. (1977) (4)
- Tmprss2:erg Rearrangement Is an Independent Marker of Good Prognosis in Prostate Cancer (2008) (4)
- Immunotherapy for renal cell carcinoma: recent results (1986) (3)
- BORON NEUTRON CAPTURE THERAPY: A MEANS OF INCREASING THE EFFECTIVENESS OF FAST NEUTRON RADIOTHERAPY (1992) (3)
- The unreliability of visual inspection to monitor skin graft survival times in AG-B-incompatible rat strains. (1974) (3)
- Cells Is Polycomb-Independent EZH 2 Oncogenic Activity in Castration-Resistant Prostate Cancer (2013) (3)
- Evaluation of radioiodinated protein conjugates and their potential metabolites containing lysine-urea-glutamate (LuG), PEG and closo-decaborate(2-) as models for targeting astatine-211 to metastatic prostate cancer. (2020) (3)
- Regulation by Zeb1 and Src Family Kinases (2011) (3)
- Comparison of fresh tissue incubation assay and the in vivo localization of monoclonal antibodies to renal cell carcinoma. (1987) (3)
- PROSTATE CANCER BONE METASTASIS: REACTIVE OXYGEN SPECIES, GROWTH FACTORS AND HEPARAN SULFATE PROTEOGLYCANS PROVIDE A SIGNALING TRIAD THAT SUPPORTS PROGRESSION (2008) (3)
- Polycomb-independent activity of EZH2 in castration resistant prostate cancer (2013) (3)
- 1915 NADIA PROSVUE™ SLOPE IDENTIFIES PATIENTS AT GREATLY REDUCED RISK FOR PROSTATE CANCER RECURRENCE FOLLOWING RADICAL PROSTATECTOMY (2011) (3)
- Identification of the target of monoclonal antibody A6H as dipeptidyl peptidase IV/CD26 by LC MS\MS. (2001) (3)
- COMMENT ON : THE VALUE OF A REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION ASSAY IN PREOPERATIVE STAGING AND FOLLOWUP OF PATIENTS WITH PROSTATE CANCE R. AUTHORS' REPLY (1999) (2)
- Identification of specific leukotriene-C4 binding sites in human fetal lung (1984) (2)
- THE LuCaP SERIES OF HUMAN PROSTATE CANCER XENOGRAFTS (1999) (2)
- On the application of parallel processing to the computation of dose arising from the internal deposition of radionuclides (1989) (2)
- Detection, isolation, and initial characterization of disseminated tumor cells following enrichment in patients with prostate cancer. (2005) (2)
- Experimental models and methods in antibody targeting of renal cell carcinoma. (2001) (2)
- Prognostic impact of post-prostatectomy PSA slope determined with a novel, nucleic acid detection immunoassay (NADiA ProsVue) for total PSA. (2011) (2)
- Preliminary studies using At-211-labeled anti-PSMA MAb for treatment of metastatic prostate cancer in a mouse model (2009) (2)
- GRM1 is An Androgen-Regulated Gene and its Expression Correlates with Prostate Cancer Progression in Pre-Clinical Models. (2016) (2)
- Corticosteroids and leukocyte blastogenesis in renal transplantation. (1979) (2)
- Value of NADiA ProsVue on the CAPRA-S nomogram for predicting postprostatectomy clinical recurrence. (2013) (2)
- Abstract 3857: Hedgehog signaling in primary prostate tumors and associated metastases (2010) (1)
- 220: Array Comparative Genomic Hybridization Analysis of Disseminated Epithelial Cells from the Blood and Bone Marrow of Men with Clinically Localized Prostate Cancer (2005) (1)
- REVERSE TRANSCRIPTASE-POLYMERASE CHAIN REACTION (RT-PCR) FOR DETECTION OF PROSTATE CANCER MICROMETASTASES IN PELVIC LYMPH NODES (LN), BONE MARROW (BM), AND PERIPHERAL BLOOD (PB) (1999) (1)
- Cancer/Testis Antigens Differentially Expressed in Prostate Cancer: Potential New Biomarkers and Targets for Immunotherapies (2019) (1)
- Abstract 1685:In vivoefficacy of PSMA ADC in combination with enzalutamide in castration-resistant prostate cancer (2015) (1)
- Assessment of the in vivo stability of some simple astatinated aryl- and nido-carboranyl-compounds (2002) (1)
- Renal cell carcinoma reactive monoclonal antibodies (1985) (1)
- SERUM HUMAN GLANDULAR KALLIKREIN (hK2) IN METASTATIC PROSTATE CANCER (1999) (1)
- Abstract 305: The biological and molecular characterization of clinically relevant prostate cancer xenograft lines (LuCaP series), including responses to therapy. (2013) (1)
- MP49-15 DOES TUMOR MICROENVIRONMENT AFFECT THE RESPONSE OF CASTRATION RESISTANT PROSTATE CANCER TO THERAPY IN BONE VS VISCERAL METASTASES? (2014) (1)
- Monoclonal antibodies in urology: review of reactivities and applications in diagnosis, staging, and therapy. (1985) (1)
- Prostate cancer bone metastases are associated with a decreased serum sRANKL/OPG ratio (2004) (1)
- Abstract 4826: Cancer/testis antigen expression pattern is a potential biomarker for prostate cancer aggressiveness (2015) (1)
- Abstract A25: Genome-wide methylation analyses in advanced-stage prostate cancer models (2012) (1)
- Polycomb-independent activity of EZH2 in castration resistant prostate cancer (2013) (1)
- Prostate cancer derived prostatic acid phosphatase promotes an osteoblastic response in the bone microenvironment (2013) (1)
- Meeting report from skeletal complications of malignancy IV (2006) (1)
- Abstract A109: Radium-223 dichloride inhibits tumor growth and tumor-induced bone growth in osteoblastic prostate cancer models (2015) (1)
- Adult UrologyOncology: Prostate/Testis/Penis/UrethraEditorial Comment (2008) (1)
- Determination of the immunoreactive fraction of radiolabeled monoclonal antibody and F(ab')2 fragment against a human renal cell carcinoma cell line (1988) (1)
- Mediated Suppression of Apoptosis − Signal Transducers and Activators of Transcription 3 Androgen-Independent Progression in Prostate Cancer via Increased Hsp 27 after Androgen Ablation Facilitates (2005) (1)
- Abstract 5205: CCND1 is a miR-193b target in prostate cancer (2014) (1)
- Preparation and evaluation of radioiodinated biotin derivatives which contain ionic charges (2001) (1)
- 435 Circulating microRNAs are associated with the development and progression of prostate cancer (2012) (1)
- Radium-223 dichloride exhibits dual mode-of-action inhibiting both tumour and tumour-induced bone growth in two osteoblastic prostate cancer models (2015) (1)
- Abstract 3447: Radium-223 dichloride exhibits dual mode-of-action inhibiting both tumor and tumor-induced bone growth in two osteoblastic prostate cancer models (2015) (1)
- Synthesis, radioiodination and evaluation of closo-decaborate(2-)-containing PSMA inhibitors for prostate cancer targeting (2010) (1)
- Utility of Tumor Markers in Testicular Tumors and Prostate Cancer (1985) (1)
- Abstract 5122: Characterizing the molecular features of ERG positive tumors in primary and castration resistant prostate cancer. (2013) (0)
- Abstract 382: Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer (2014) (0)
- Estrogen Effects onTubulin Expression andTaxane MediatedCytotoxicity in ProstateCancerCells (2005) (0)
- Epithelial mesenchymal-like transition occurs in a subset of cells in castration resistant prostate cancer bone metastases (2015) (0)
- 140 PROSTATE CANCER CELL TYPES BASED ON GENE EXPRESSION (2011) (0)
- 439: Protease Activated Receptors (PAR) Mediate Migration in Prostate Cancer Cells Through Rho-Gtpase Signaling Pathways (2006) (0)
- Abstract 5237: Interrogating cell heterogeneity and dormancy in prostate cancer disseminated tumor cells (2012) (0)
- Dormancy in solid tumors: implications for prostate cancer (2013) (0)
- Abstract 5603: Response of human prostate cancer xenografts to IGF-IR inhibition correlates with PTEN and androgen receptor splice variant status (2012) (0)
- The biology and clinical implications of prostate cancer dormancy and metastasis (2015) (0)
- Frequent somatic mutations of the ATBF1 transcription factor in human prostate cancer (2005) (0)
- Abstract 735: Evaluation of cabozantinib in combination with abiraterone, enzalutamide or docetaxel in a castration-resistant prostate cancer xenograftin vivo (2014) (0)
- The Prostate 70 : 1799 ^ 1808 ( 2010 ) InhibitionofAngiopoietin-2 in LuCaP 23 . 1 Prostate CancerTumorsDecreasesTumorGrowthandViability (2010) (0)
- EZH2 GENE IS AMPLIFIED IN LATE-STAGE PROSTATE CANCERS (2006) (0)
- Tsai and De Morais et al 1 Cyclin D 1 Loss Distinguishes Prostatic Small Cell Carcinoma from Most Prostatic Adenocarcinomas (2015) (0)
- IMMUNOLOCALIZATION OF SCF AND C-KIT IN BENIGN AND MALIGNANT PROSTATIC TISSUE (2008) (0)
- Abstract 3242: The molecular and biological characterization of 25 unique prostate cancer xenograft lines, including response to therapy (2010) (0)
- EVALUATION OF SUCCINYLATED STREPTAVIDIN AS THE RADIONUCLIDE CARRIER IN ANTIBODY PRETARGETING OF PROSTATE CANCER (2000) (0)
- Abstract 1989: SRRM4 and the loss of REST may promote the emergence of the neuroendocrine /neuronal phenotype in castration resistant prostate cancer (2014) (0)
- Are Circulating Phospholipid Fatty Acids a Reasonable Surrogate for Levels in The Prostate? (2017) (0)
- 433: Increased Protease Activated Receptor (PAR) Expression and RhoA Signaling in Prostate Cancer (2004) (0)
- A new mechanism of estrogen action in prostate cancer: Inhibition of tissue androgen production and prostate cancer growth by Estradiol in androgen independent prostate cancer xenografts (2007) (0)
- Abstract 3504: Targeting the Akt pathway and HDAC signaling in prostate cancer (2011) (0)
- Valproic acid inhibits prostate cancer cell growth. (2004) (0)
- 554 INCREMENTAL EXPRESSION OF PITX2, A WNT PATHWAY ASSOCIATED TRANSCRIPTION FACTOR IN PRIMARY AND METASTATIC PROSTATE CANCER (2010) (0)
- EFFECT OF ANDROGEN DEPRIVATION THERAPY ON DISSEMINATED TUMOR CELLS IN MEN WITH PROSTATE CANCER (2009) (0)
- Evaluation of effects of over-expression of osteoprotegerin in C4-2 prostate cancer cells on character of bone metastasis (2004) (0)
- Abstract A219: Universal efficacy of novel androgen receptor pure antagonist, CH5137291, against broad spectrum prostate cancer including castration‐resistant prostate cancers (2009) (0)
- Prostate Cancer in Lymph Nodes Transcription-PCR for the Detection of Micrometastatic Comparison of Immunohistochemistry with Reverse Updated Version (2003) (0)
- Tumors Cyclin D 1 Loss Distinguishes Prostatic Small-Cell Carcinoma fromMost Prostatic Adenocarcinomas (2015) (0)
- Specific imaging of renal cell carcinoma xenografts using monoclonal antibodies (1984) (0)
- Imaging , Diagnosis , Prognosis Human Prostate Cancer in a Clinically Relevant Xenograft Mouse Model : Identi fi cation of b ( 1 , 6 )-Branched Oligosaccharides as a Marker of Tumor Progression (2012) (0)
- Abstract 1532: The identification of osteoblastic and osteolytic factors in prostate cancer bone metastases (2012) (0)
- Detection of circulating prostate cells in patients with clinically localized carcinoma of the prostate (CAP) (1997) (0)
- INACTIVATION OF DECAY-ACCELERATOR ACTIVITY OF FACTOR H BY MONOCLONAL ANTIBODIES: IMPLICATIONS FOR BLADDER CANCER THERAPY (1999) (0)
- Abstract 3302: Profiling prostate cancer metastases (2010) (0)
- Branched chain DNA assay for accurate measurement of RNA in formalin-fixed tissues (2006) (0)
- LowDose,AlternatingElectricCurrentInhibits GrowthofProstateCancer (2009) (0)
- LineageRelationship BetweenLNCaPand LNCaP-Derived ProstateCancerCell Lines (2004) (0)
- First International Workshop on Focal Therapy and Imaging of Prostate Cancer (2018) (0)
- Abstract 406: Characterizing the molecular features of the neuroendocrine phenotype in castration resistant prostate cancer. (2013) (0)
- Abstract 631: Androgen receptor(AR) splice variants inhibit responses to IGF-IR inhibition in prostate cancer (2010) (0)
- The Prostate LowDose , Alternating Electric Current Inhibits Growthof ProstateCancer (2009) (0)
- Prostate-specific Membrane Antigen Directed Selective Thrombotic Infarction of Tumors 1 (2002) (0)
- Abstract 737: Assessment of cabozantinib activity in diverse prostate cancer xenograft models (2014) (0)
- Abstract 5249: LuCaP prostate cancer xenografts: Models that allow clinically relevant investigation of prostate cancer in a preclinical setting (2012) (0)
- Persistence of disseminated tumor cells after radical prostatectomy: implications for tumor dormancy (2007) (0)
- A brief review of ultrasensitive prostate-specific antigen assays for the evaluation of patients after radical prostatectomy (2004) (0)
- PSA RT-PCR: current status and future potential (1998) (0)
- Abstract 1214: Preclinical models of prostate cancer: New patient-derived xenografts for preclinical studies and evaluation of prostate cancer biology (2014) (0)
- Prostate cancer metastasis, the noncanonical Wnt pathway, and the transcription factor PITX2. (2010) (0)
- Validation of the QuantiGene FFPE-branched chain DNA assay for measurement of gene expression in formalin-fixed clinical tissue samples. (2007) (0)
- 415: Mutational Analysis of the P63 Gene in Prostate Cancer Cells (2004) (0)
- THE PROSTATE EXPRESSION DATABASE: A TOOL FOR NOVEL GENE DISCOVERY AND THE VIRTUAL ANALYSIS OF PROSTATE GENE EXPRESSION (1999) (0)
- 332 PROSTATE CANCER DISSEMINATED TUMOR CELL HETEROGENEITY AND DORMANCY (2013) (0)
- MP62-18 CONVERSION OF ADENOCARCINOMA TO SMALL CELL CARCINOMA-LIKE BY REPROGRAMMING (2016) (0)
- 1924 ANALYSIS OF A CIRCULATING MICROVESICLE-BASED ASSAY IN AT-RISK PATIENTS FOR THE DETECTION OF PROSTATE CANCER (2011) (0)
- Yolk Sac Tumors In Vitro: A Model to Study Aspects of Early Embryonic Yolk Sac Function (1987) (0)
- Evaluation of lysine-urea-glutamate derivatives that contain closo-decaborate(2-) moieties for targeting astatine-211 to metastatic prostate cancer (2014) (0)
- How important are the prostate-specific antigen assays? (1994) (0)
- Abstract 486: The novel tumor suppressorDIAPH3governs transition to an amoeboid phenotype (2012) (0)
- Inhibition of IGF-IR signaling with the human monoclonal antibody A12 enhances the therapeutic effect of docetaxelin prostate cancer (2005) (0)
- 2134 DIFFERENTIAL EXPRESSION OF AGR2 AND CD10 IN PROSTATE CANCER (2013) (0)
- Increased expression of the protease-activated receptor by prostate cancer cells and PAR-mediated activation of the MAP kinase signaling pathway (2003) (0)
- Abstract 4859: Tumor growth inhibition and epigenetic changes following protein diet restriction in a human prostate cancer model. (2013) (0)
- 434: Membrane Type-1 Matrix Metalloproteinase (MT1-MMP) Promotes Tumor Growth and Bone Degradation in Prostate Cancer Bone Metastasis (2006) (0)
- PCR DETECTION OF POLYMORPHISMS IN A SHORT TANDEM REPEAT 3' TO THE HUMAN PHOSPHOGLYCERATE KINASE GENE IN CAUCASIAN PROSTATE CANCER PATIENTS (1999) (0)
- Abstract 2855: Anti-PSMA x anti-CD3 SCORPIONTMmolecule inhibits tumor growthin vivoin mouse models of prostate cancer. (2013) (0)
- FGF and MAPK pathways are active in AR-null prostate cancer d Autocrine and paracrine FGF pathway activation can bypass AR dependence d Targeting the FGF and MAPK pathways can repress AR-null prostate cancer (0)
- Evaluation of the effects of prostate specific antigen (PSA) on prostate cancer bone metastasis (2006) (0)
- Abstract 2133:In vivoefficacy of PSMA ADC in castration-resistant prostate cancer. (2013) (0)
- Abstracts from the First International Workshop on Focal Therapy and Imaging of Prostate Cancer, February 21-22, 2008, the Duke Comprehensive Cancer Center and the Duke Prostate Center, Durham, North Carolina (2008) (0)
- Potentials and Limitations of Monoclonal Antibody (MAB) – Targeted Radiotherapy for Renal Cell Carcinoma (RCC) (1987) (0)
- Abstract 439: Glycosylation of α-dystroglycan in prostate cancer: Prognostic implications and regulation by LARGE2 (2012) (0)
- An AntibodyTargeting theType I Insulin-like Growth Factor Receptor Enhances theCastration-InducedResponseinAndrogen-Dependent ProstateCancer (2007) (0)
- TheCurrent State of Preclinical ProstateCancerAnimalModels (2008) (0)
- Abstract C34: The biological and molecular characterization of 28 unique prostate cancer xenograft lines (LuCaP series), including responses to therapy (2012) (0)
- ' s response to reviews Title : Host-Derived RANKL is Responsible for Osteolysis in C 4-2 Human Prostate Cancer Xenograft Model of Experimental Bone Metastases (2007) (0)
- Abstract PR6: Cabozantinib (XL184) inhibits androgen-sensitive and castration-resistant prostate cancer in the bone and increases bone formation in non-tumored bones (2012) (0)
- Abstract 1583: The biological and molecular characterization of 24 unique prostate cancer xenograft lines, including responses to therapy (2011) (0)
- Abstract 1937: Nemo-like kinase expression is altered during prostate cancer progression (2011) (0)
- Angiogenesis , Metastasis , and the Cellular Microenvironment Loss of TGF-b Responsiveness in Prostate Stromal Cells Alters Chemokine Levels and Facilitates the Development of Mixed Osteoblastic / Osteolytic Bone Lesions (2012) (0)
- Analysis of blood-derived circulating microvesicles for microRNA biomarkers of metastatic and nonmetastatic prostate cancer. (2011) (0)
- Identifying biomarkers specific to bone metastases in castrate-resistant prostate cancer. (2014) (0)
- Increased expression of CD44 and other cell surface molecules by cultured prostatic cells (1999) (0)
- Abstract 3620: LIV-1 antibody-drug conjugate: A novel therapeutic agent for breast and prostate cancer (2011) (0)
- Prostate StemCell Antigen Is Overexpressed in Prostate (2005) (0)
- 63 Radium-223 dichloride – Efficacy and mode-of-action in a mouse model of prostate cancer bone metastasis (2014) (0)
- 837: Detection and Isolation of PSA Positive Epithelial Cells by Enrichment: Comparison to Standard PSA RT-PCR, Clinical Relevance, and Initial Characterization in Prostate Cancer Patients (2004) (0)
- SERIAL PROSTATE SPECIFIC ANTIGEN (PSA) AND FREE/TOTAL PSA (F/T PSA) RATIO IN THE DIAGNOSIS OF PROSTATE CANCER (1999) (0)
- 1621 SINGLE CELL TRANSCRIPTOMIC PROFILING OF PROSTATE CANCER CELLS (2011) (0)
- Post-prostatectomy PSA slope (ProsVue) in Gleason score ≥7 disease (2012) (0)
- Prostate Cancer Therapy Resistance Constitutively Active Androgen Receptor that Mediates Exon Generates a Androgen Receptor Splicing of a Novel Updated (2008) (0)
- Abstract 5242: Obtaining a transcriptomic profile of a single prostate cancer cell (2011) (0)
- Abstract 804: Disseminated tumor cell heterogeneity and dormancy in prostate cancer. (2013) (0)
- RIS 1 GTAAGCCCATTGAGTCCACGC TCACTTGGTCGCCACCCCCGA ChGn TGCAGCAGTGCCTTTCGATAG GTCGAAATAAGATGAGCCGTTTGA TNC CAGACATCACTGAAAATTCGGCTAC GCAAAGATTCTCAGTGTGTATTCCG EDNRB GCAAACCGCAGAGATAATGACG TCAAGATATTGGGACCGTTTCG STC 2 CAAGTCATTCATCAAAGACGCCTT CCTTTCATTTCACCTCCGGATATC BF ACTCCATGGTCTTTGGCCCAG AGTGGATTG (2015) (0)
- PHENOTYPIC HETEROGENEITY IN DISSEMINATED PROSTATE CANCER TUMOR CELLS: IMPLICATIONS IN EPITHELIAL TO MESENCHYMAL TRANSITION (2009) (0)
- Abstract 5059: Exome and targeted sequencing to discover and validate candidate genes in advanced and lethal prostate cancer (2012) (0)
- Abstract 1718: The importance of clinically relevant rapid autopsy specimens and LuCaP patient-derived xenograft models to interrogate the heterogeneous and evolving treatment resistance of castration-resistant prostate cancer (2015) (0)
- Detection of Prostate-Cancer Cells in Blood and Bone Marrow by RT-PCR (1998) (0)
- Corrigendum: Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer (2005) (0)
- Abstract IA21: AR is ablated: Now what? Targeting the double-negative phenotype (2018) (0)
- Methods of selecting monoclonal antibodies for radioimmunodetection using a fresh tissue incubation assay in renal cell carcinoma (1985) (0)
- Plasma Fatty Acids as Surrogate for Prostate Levels (2018) (0)
- 685 EPITHELIAL-MESENCYHMAL TRANSITION IN PROSTATE CANCER DISSEMINATED TUMOR CELLS (2010) (0)
- Abstract 4011: Single cell transcriptomic analysis identified a potential dormant signature in prostate cancer disseminated tumor cells (2014) (0)
- ' s response to reviews Administration of Zoledronic Acid Enhances the Effects of Docetaxel on Growth of Prostate Cancer in Title : the Bone Environment (2005) (0)
- Abstract 2329: Alterations in laminin expression modulate prostate cancer cell behavior through changes in integrin and insulin-like growth factor receptor actions (2010) (0)
- Abstract #5524: Chemotherapy-induced monoamine oxidase A expression in prostate carcinoma associates with clinical outcome and functions as a cytoprotective resistance enzyme through HIF1 pathway (2009) (0)
- Does the Phenotyping of Disseminated Prostate Cancer Cells in Blood and Bone Marrow Prior to Radical Prostatectomy Provide Prognostic Information (2002) (0)
- Abstract 849: Cabozantinib (XL184) inhibits growth of prostate cancer in the bone and results in an altered bone environment (2012) (0)
- 2334 PROSAPOSIN, A NOVEL BIOMARKER FOR PRIMARY AND METASTATIC PROSTATE CANCER (2011) (0)
- WWP1 E3 ubiquitin ligase is a potential oncogene in human prostate and breast cancer (2006) (0)
- ComprehensiveMutationalAnalysis andmRNA IsoformQuantificationofTP63 inNormaland NeoplasticHumanProstateCells (2009) (0)
- Abstract 4313: Abiraterone acetate (AA) treatment of prostate cancer patient-derived xenografts (PDX) demonstrates heterogeneity of responses and identifies potential biomarkers of adaptive resistance (2015) (0)
- Abstract 1093: The role of cellular adhesion in escaping prostate cancer tumor dormancy. (2013) (0)
- Radioimmunoscintigraphy and radioimmunotherapy with RCC MABS (1985) (0)
- ヒト腎細胞癌に対するモノクローナル抗体Ｃ５ＨのＦ（ａｂ′）２フラグメントの免疫学的活動に関する研究 (1988) (0)
- TSC-22 is a potential pro-apoptotic prostate tumor suppressor gene regulated by androgen and IGF-IR signaling in prostate epithelium (2006) (0)
- Abstract 1118: Circulating microRNA biomarkers for cancer exist in multiple biophysical states. (2013) (0)
- 657: Disseminated Tumor Cells in Prostate Cancer: Implications for Systemic Progression and Tumor Dormancy (2007) (0)
- Abstract 4525: Cancer/testis antigens: A biomarker panel for prostate cancer screening (2018) (0)
- Abstract B31: Establishing the use of genomic profiling on rare prostate cancer disseminated tumor cells (2012) (0)
- S29 02 TA – BORON NEUTRON CAPTURE THERAPY: A MEANS OF INCREASING THE EFFECTIVENESS OF FAST NEUTRON RADIOTHERAPY (1991) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Robert L. Vessella?
Robert L. Vessella is affiliated with the following schools:
